AVROBIO, Inc. (AVRO) gained significantly in the pre-market after the company announced Phase ½ clinical trial results for cystinosis. AVRO values at $1.80, gaining more
Avrobio Inc. (AVRO) stock jumped by a further 6.51% in the premarket hours, at $4.09 on December 14. In the previous regular trading session, the
At Stocktstelegraph.com, we are committed to helping investors make smart and profitable decisions. Our goal is to make investing easier and more accessible to everyone. We strive to provide the best and most reliable market information, news and analysis to ensure that our readers can make informed decisions.